ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

ClinicalTrials.gov ID: NCT02875548

Public ClinicalTrials.gov record NCT02875548. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study

Study identification

NCT ID
NCT02875548
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Epizyme, Inc.
Industry
Enrollment
58 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 29, 2016
Primary completion
Sep 25, 2025
Completion
Sep 25, 2025
Last update posted
Nov 3, 2025

2016 – 2025

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
University of Arizona Cancer Center Tucson Arizona 85724
California Cancer Associates For Research And Excellence, cCARE Santa Fe California 92024
Hematology Oncology Associates of the Treasure Coast - Port St. Lucie Port Saint Lucie Florida 34952
Moffitt Tampa Florida 33612
Dana-Farber Cancer Institute Boston Massachusetts 02215
University of Michigan Ann Arbor Michigan 48109
Central Care Cancer Center Bolivar Missouri 65613
Astera Cancer Center East Brunswick New Jersey 08816
Columbia University Medical Center New York New York 10019
David H. Koch Center for Cancer Care at memorial Sloan Kettering Cancer Center New York New York 10065
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center Pittsburgh Pennsylvania 15232

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02875548, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 3, 2025 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02875548 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →